We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Precision Screening Helps Close Hepatitis C Diagnosis and Treatment Gaps

By LabMedica International staff writers
Posted on 07 Aug 2026

Hepatitis C remains a leading cause of cirrhosis and liver cancer, yet many infections go undiagnosed or untreated because health systems fail to reach those at greatest risk. More...

Although highly effective antiviral therapies are available, persistent gaps in screening, confirmatory testing, and linkage to care continue to limit disease control. New findings show that a countywide precision screening program combined with decentralized treatment substantially improved case detection, treatment initiation, and projected health outcomes.

National Taiwan University and collaborating institutions developed an integrated hepatitis C elimination program across Changhua County, Taiwan, combining risk-based screening with decentralized, community-based care. Rather than relying solely on population-wide screening, the model prioritizes high-risk groups, including people with chronic kidney disease, diabetes, human immunodeficiency virus (HIV), individuals who inject drugs, incarcerated populations, and dialysis patients. Services are embedded within existing community health resources and integrate targeted screening, rapid diagnosis, confirmatory RNA testing, and locally delivered treatment.

In a study involving more than 1.27 million residents, published in Nature Communications, the program increased hepatitis C screening coverage from 53.7% to 90.2%. Confirmatory RNA testing doubled, treatment initiation reached 91.6%, and modern antiviral therapy achieved a 99% cure rate. Advanced statistical modeling projected reductions in liver cancer incidence and liver-related mortality sufficient to meet World Health Organization (WHO) hepatitis C elimination targets by 2030.

For clinical laboratories, the targeted approach increased demand for confirmatory RNA testing while directing diagnostic resources toward populations with the highest pretest probability. The Changhua program demonstrates how precision public health, integrated care networks, and data-driven decision-making can improve progression from screening through treatment and accelerate hepatitis C elimination.

“Our study demonstrates that hepatitis C elimination depends not only on effective medicines but also on delivering the right care to the right people at the right time. By integrating precision risk-based screening with community-based health care, we provide a practical model that can help countries worldwide accelerate progress toward hepatitis C elimination,” said co-corresponding author Tony Hsiu-Hsi Chen of the Institute of Health Data Analytics and Statistics at National Taiwan University.

Related Links
National Taiwan University


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Pre- Eclampsia Control
Acusera Pre-Eclampsia Control
All-in-One Molecular System
AIO M160
POC Immunoassay Analyzer
Procise DX
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Pathology

view channel
Image: Researchers evaluated AI models that quantify tumor-infiltrating lymphocytes (TIL) on routine breast tissue slides, where higher TIL levels reflect stronger antitumor response and improved breast cancer outcomes (Image Credit: Shutterstock)

AI Matches Pathologists in Predicting Breast Cancer Prognosis from Immune Cells

Breast cancer is the most common cancer in Australian women, with more than 20,000 cases each year. Prognosis can be informed by counting tumor-infiltrating lymphocytes (TILs) on routine pathology slides,... Read more

Industry

view channel
Image Credit: Adobe Stock

Companion Diagnostics Expand HER2 Testing in Metastatic Gastroesophageal Cancer

Gastroesophageal adenocarcinoma comprises a group of aggressive cancers that are often diagnosed at an advanced stage and carry poor prognoses. Gastric and esophageal cancers rank among the leading causes... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.